These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28278514)

  • 1. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
    Bae JM; Kim JH; Kwak Y; Lee DW; Cha Y; Wen X; Lee TH; Cho NY; Jeong SY; Park KJ; Han SW; Lee HS; Kim TY; Kang GH
    Br J Cancer; 2017 Apr; 116(8):1012-1020. PubMed ID: 28278514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
    BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
    Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
    Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between molecular subtypes of colorectal cancer and patient survival.
    Phipps AI; Limburg PJ; Baron JA; Burnett-Hartman AN; Weisenberger DJ; Laird PW; Sinicrope FA; Rosty C; Buchanan DD; Potter JD; Newcomb PA
    Gastroenterology; 2015 Jan; 148(1):77-87.e2. PubMed ID: 25280443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
    Ito M; Mitsuhashi K; Igarashi H; Nosho K; Naito T; Yoshii S; Takahashi H; Fujita M; Sukawa Y; Yamamoto E; Takahashi T; Adachi Y; Nojima M; Sasaki Y; Tokino T; Baba Y; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
    Int J Cancer; 2014 Dec; 135(11):2507-15. PubMed ID: 24752710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
    O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
    Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtypes of the Type II Pit Pattern Reflect Distinct Molecular Subclasses in the Serrated Neoplastic Pathway.
    Aoki H; Yamamoto E; Yamano HO; Sugai T; Kimura T; Tanaka Y; Matsushita HO; Yoshikawa K; Takagi R; Harada E; Nakaoka M; Yoshida Y; Harada T; Sudo G; Eizuka M; Yorozu A; Kitajima H; Niinuma T; Kai M; Nojima M; Suzuki H; Nakase H
    Dig Dis Sci; 2018 Jul; 63(7):1920-1928. PubMed ID: 29546645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.
    Bae JM; Kim MJ; Kim JH; Koh JM; Cho NY; Kim TY; Kang GH
    Virchows Arch; 2011 Jul; 459(1):55-63. PubMed ID: 21494758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.
    Phipps AI; Alwers E; Harrison T; Banbury B; Brenner H; Campbell PT; Chang-Claude J; Buchanan D; Chan AT; Farris AB; Figueiredo JC; Gallinger S; Giles GG; Jenkins M; Milne RL; Newcomb PA; Slattery ML; Song M; Ogino S; Zaidi SH; Hoffmeister M; Peters U
    Gastroenterology; 2020 Jun; 158(8):2158-2168.e4. PubMed ID: 32088204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.